Figure 3.

Histological assessment of minor salivary gland biopsies. (A), (B) Histological scoring of minor salivary gland (MSG) biopsies in the rituximab (RTX) and disease-modifying anti-rheumatic drug (DMARD) treatment groups at baseline and week 120. (C), (D) Percentage of CXCR4-positive cells and CXCR5-positive cells inside the glandular infiltrate. Bars indicate mean ± standard error of the mean. ***P <0.001, **P <0.01 and *P <0.05. (E) Percentage of patients displaying germinal centers (GCs) in the RTX and DMARD treatment groups at baseline and week 120. MNC, mononuclear cells.

Carubbi et al. Arthritis Research & Therapy 2013 15:R172   doi:10.1186/ar4359
Download authors' original image